Hydrochlorothiazide and indapamide are thought to exert their hypotensive e
fficacy through a combined vasodilator and diuretic effect, but in vivo evi
dence for a direct vascular effect is lacking. The presence and mechanism o
f a direct vascular action of hydrochlorothiazide in vivo in humans were ex
amined and compared with those of the thiazide-like drug indapamide. Forear
m vasodilator responses to infusion of placebo and increasing doses of hydr
ochlorothiazide (8, 25, and 75 mu g . min(-1) . dL(-1)) into the brachial a
rtery were recorded by venous occlusion plethysmography. Dose-response curv
es were repeated after local tetraethylammonium (TEA) administration to det
ermine the role of potassium channel activation and, in patients with the G
itelman syndrome, to determine the role of the thiazide-sensitive Na-Cl cot
ransporter in the vasodilator effect of hydrochlorothiazide. Vascular effec
ts of hydrochlorothiazide were compared with those of indapamide in both no
rmotensive (mean arterial pressure, 85+/-7 mm Hg) and hypertensive (mean ar
terial pressure, 124+/-16 mm Hg) subjects. At the highest infusion rate, lo
cal plasma concentrations of hydrochlorothiazide averaged 11.0+/-1.6 mu g/m
L, and those of indapamide averaged 7.2+/-1.5 mu g/mL. In contrast to indap
amide, hydrochlorothiazide showed a direct vascular effect (maximal vasodil
ation, 55+/-14%; P=0.013), which was inhibited by TEA (maximal vasodilation
after TEA, 13+/-10%; P=0.02). The response was not dependent on blood pres
sure and was similar in patients with Gitelman syndrome, indicating that ab
sence of the Na-CI cotransporter does not alter the vasodilatory effect of
hydrochlorothiazide. The vasodilator effect of hydrochlorothiazide in the h
uman forearm is small and only occurs at high concentrations. The mechanism
of action is not mediated by inhibition of vascular Na-Cl cotransport but
involves vascular potassium channel activation. In contrast, indapamide doe
s not exert any direct vasoactivity in the forearm vascular bed.